Bringing the fundamentals into focus…
Back to MoonLake Immunotherapeutics
How MoonLake Immunotherapeutics stacks up
MLTX · against 469 other Healthcare companies of similar size
Profitability
9/ 100
Near the bottom of its peers.
Ranked #435 of 470 · scores higher than 7% of peers
Bars: peers in each 10-point band of the profitability score36 peers with a profitability score of 0–9, including MLTX · Click a bar to see the companies
Why profitability scores 9?
Weighted metrics compared with all Healthcare companies.Mainly because of its return on invested capital and return on assets, which are weaker than most Healthcare peers.
- a lower return on invested capital: weaker than 98% of peers. Return on invested capital: -425.6% vs peer median 4.7%
- a lower return on assets: weaker than 92% of peers. Return on assets: -45.9% vs peer median 1.7%
- Operating margin is not reported, so it is left out of the score.
Metric by metric
Position: dot = MLTX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | MLTX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Return on invested capitalHigher is better · 448 reported | -425.6% | 4.4% | 2% | 33% | |
| Operating marginHigher is better · 440 reported | Not reported | 6.7% | — | — | 33% |
| Return on assetsHigher is better · 456 reported | -45.9% | 1.5% | 6% | 33% | |
| Return on equityHigher is better · 438 reported | -67.5% | 2.7% | 10% | Context only | |
| Gross marginHigher is better · 489 reported | 0.0% | 46.2% | 3% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by profitability score
Top 5 and the companies ranked around MLTX| Rank | Company | Market cap | Profitability | Overall |
|---|---|---|---|---|
| 1 | 97.3B INR (≈$1.2B) | 100 | 80 | |
| 2 | 12.3B CNY (≈$1.7B) | 99 | 85 | |
| 2 | 595M USD | 99 | 97 | |
| 2 | 11.2B DKK (≈$1.7B) | 99 | 59 | |
| 2 | 578M USD | 99 | 73 | |
| 433 | 504M USD | 10 | 24 | |
| 433 | 588M USD | 10 | 24 | |
| 435 | 9.9B HKD (≈$1.3B) | 9 | 17 | |
| 435 | 1.3B USD | 9 | 15 | |
| 435 | 996M USD | 9 | 35 | |
| 435 | 730M USD | 9 | 11 | |
| 439 | 1.9B USD | 8 | 18 | |
| 439 | 885M USD | 8 | 33 | |
| 441 | 1.1B USD | 7 | 26 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score